Total Payments
$65,767
2024 Payments
$7,185
Companies
17
Transactions
70
Medicare Patients
1,774
Medicare Billing
$441,113
Payment Breakdown by Category
Consulting$55,749 (84.8%)
Other$5,116 (7.8%)
Travel$2,693 (4.1%)
Food & Beverage$1,313 (2.0%)
Research$784.45 (1.2%)
Education$111.06 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $55,749 | 27 | 84.8% |
| Honoraria | $4,616 | 3 | 7.0% |
| Travel and Lodging | $2,693 | 15 | 4.1% |
| Food and Beverage | $1,313 | 16 | 2.0% |
| Unspecified | $784.45 | 6 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 | 0.8% |
| Education | $111.06 | 2 | 0.2% |
Payments by Type
General
$64,983
64 transactions
Research
$784.45
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $15,013 | 16 | $0 (2024) |
| Amgen Inc. | $9,459 | 10 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,857 | 8 | $0 (2022) |
| Genentech, Inc. | $6,340 | 3 | $0 (2019) |
| EMD Serono, Inc. | $4,238 | 5 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $3,908 | 3 | $0 (2023) |
| Genentech USA, Inc. | $3,833 | 5 | $0 (2023) |
| PFIZER INC. | $2,600 | 2 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500 | 2 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $2,293 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,185 | 8 | EMD Serono, Inc. ($3,800) |
| 2023 | $9,188 | 14 | Amgen Inc. ($3,894) |
| 2022 | $12,567 | 11 | AstraZeneca Pharmaceuticals LP ($2,398) |
| 2021 | $9,971 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($5,305) |
| 2020 | $7,904 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($3,454) |
| 2019 | $12,713 | 23 | Amgen Inc. ($5,565) |
| 2017 | $6,240 | 2 | Genentech, Inc. ($6,240) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,050.00 | General |
| 09/08/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $118.38 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $356.47 | Research |
| Study: A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $96.38 | Research |
| Study: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $92.36 | Research |
| Study: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 03/29/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $146.90 | Research |
| Study: A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | ||||||
| 12/02/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $52.71 | General |
| 12/02/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $38.41 | General |
| 12/01/2023 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $220.10 | General |
| 12/01/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $126.52 | General |
| 11/11/2023 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| Category: Oncology | ||||||
| 08/15/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $129.35 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/03/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $99.43 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $65.87 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $26.47 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 04/25/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| Category: ONCOLOGY | ||||||
| 04/13/2023 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 01/04/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,596.00 | General |
| Category: Oncology | ||||||
| 01/04/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,298.00 | General |
| Category: Oncology | ||||||
| 12/02/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: Oncology | ||||||
| 11/22/2022 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $757.50 | General |
| Category: Oncology | ||||||
| 09/29/2022 | PFIZER INC. | XALKORI (Drug) | Honoraria | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Retrospective and Prospective Natural History Study to Examine the Characteristics of Gene-Related Hearing Loss in Pediatric Participants With Biallelic Otoferlin (OTOF) Mutations, Gap Junction Beta 2 (GJB2) Mutations, Or Digenic GJB2/Gap Junction Beta 6 (GJB6) Mutations | Regeneron Pharmaceuticals, Inc. | $356.47 | 1 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $188.74 | 2 |
| A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS | Regeneron Pharmaceuticals, Inc. | $146.90 | 1 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | AbbVie Inc. | $92.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 486 | 869 | $655,797 | $100,069 |
| 2022 | 9 | 514 | 979 | $788,578 | $133,272 |
| 2021 | 6 | 413 | 850 | $482,230 | $121,718 |
| 2020 | 7 | 361 | 737 | $414,679 | $86,054 |
Total Patients
1,774
Total Services
3,435
Medicare Billing
$441,113
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 153 | 405 | $279,045 | $43,374 | 15.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 103 | 171 | $167,409 | $25,710 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $69,084 | $11,300 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 72 | 89 | $43,966 | $7,103 | 16.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 56 | $38,584 | $4,586 | 11.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 37 | $36,223 | $4,123 | 11.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 30 | $18,150 | $3,558 | 19.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 11 | 24 | $3,336 | $314.91 | 9.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 111 | 353 | $345,587 | $60,479 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 322 | $221,858 | $36,957 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 45 | 80 | $78,320 | $10,932 | 14.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 43 | 43 | $52,116 | $9,139 | 17.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 32 | $19,360 | $4,128 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 27 | 35 | $24,115 | $3,110 | 12.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 43 | $13,846 | $2,902 | 21.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 24 | $11,040 | $2,323 | 21.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 15 | $8,760 | $1,424 | 16.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 14 | $6,916 | $1,178 | 17.0% |
| 99449 | Telephone or internet assessment with verbal and written report by consulting physician, more than 30 minutes | Office | 2022 | 15 | 18 | $6,660 | $700.33 | 10.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 132 | 315 | $201,915 | $54,082 | 26.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 146 | 373 | $177,175 | $44,373 | 25.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 58 | 58 | $53,302 | $12,468 | 23.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 29 | 30 | $18,150 | $3,940 | 21.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 23 | 30 | $17,520 | $3,721 | 21.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 44 | $14,168 | $3,134 | 22.1% |
About Dr. Nagashree Seetharamu, MD
Dr. Nagashree Seetharamu, MD is a Internal Medicine healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124198833.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nagashree Seetharamu, MD has received a total of $65,767 in payments from pharmaceutical and medical device companies, with $7,185 received in 2024. These payments were reported across 70 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($55,749).
As a Medicare-enrolled provider, Seetharamu has provided services to 1,774 Medicare beneficiaries, totaling 3,435 services with total Medicare billing of $441,113. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hospice and Palliative Medicine, Hematology & Oncology
- Location New Hyde Park, NY
- Active Since 11/09/2006
- Last Updated 02/02/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124198833
Products in Payments
- TECENTRIQ (Biological) $5,678
- IMFINZI (Drug) $4,590
- RYBREVANT (Drug) $3,908
- LUMAKRAS (Drug) $3,894
- TAGRISSO (Drug) $3,450
- Non-Covered Product (Drug) $3,120
- IMFINZI (Biological) $2,923
- ALUNBRIG (Drug) $2,750
- EXKIVITY (Drug) $2,555
- GILOTRIF (Drug) $2,500
- LIBTAYO (Biological) $2,293
- Lenvima (Drug) $2,280
- XALKORI (Drug) $1,600
- BRAFTOVI (Drug) $500.00
- ZEPZELCA (Drug) $347.16
- NovoTTF-100L (Device) $13.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New Hyde Park
Dr. Michael Levine, Md, MD
Internal Medicine — Payments: $394,059
Internal Medicine $394,059
Nikhil Sharma, M.d, M.D
Internal Medicine — Payments: $89,735
Internal Medicine $89,735
Dr. Abhinav Agrawal, M.d, M.D
Internal Medicine — Payments: $49,576
Internal Medicine $49,576
Dr. Thomas Mathew, Md, MD
Internal Medicine — Payments: $47,542
Internal Medicine $47,542
Dr. Kennedy Omonuwa, M.d, M.D
Internal Medicine — Payments: $45,556
Internal Medicine $45,556
Lydia Gorski, M.d, M.D
Internal Medicine — Payments: $21,738
Internal Medicine $21,738